Schlag R, Flieger D, Ziegler-Heitbrock H W, Hill W, Emmerich B, Thiel E
Medizinische Klinik Innenstadt, Universität München.
Dtsch Med Wochenschr. 1990 Jul 13;115(28-29):1088-95. doi: 10.1055/s-2008-1065125.
In a clinical phase II study nine patients (five men and four women; mean age 48 [42-58] years) in an early stage of chronic lymphatic leukaemia (CLL) of the B-cell type were treated with recombinant alpha-2b interferon (IFN alpha-2b), initially at a dosage of 5 mega units subcutaneously three times weekly, but in some cases reduced to 2.5 or raised to 10 mega units. Duration of treatment has been 15-36 months. Through-flow cytometry in seven patients demonstrated a definite fall in circulating B1-positive lymphocytes. Lasting partial remission (duration of 106-134 weeks) was achieved in four patients, in a further four the condition remained stable. A recurrence was noted in the patient with the initially highest lymphocyte count (52,000/microliters) after 28 weeks, control being achieved only after 64 weeks of chemotherapy. Side effects were flu'-like symptoms and (in two instances) depression. In three patients there was a clear rise in serum immunoglobulin concentrations as sign of IFN alpha-2b-induced increased immune response, while in four HLA-DR expression on monocytes was doubled. It is concluded that early treatment of CLL with IFN alpha-2b may delay the onset of necessary chemotherapy, any antibody-deficiency may be improved and survival time may ultimately be lengthened.
在一项临床II期研究中，对9例B细胞型慢性淋巴细胞白血病（CLL）早期患者（5例男性，4例女性；平均年龄48[42 - 58]岁）采用重组α-2b干扰素（IFNα-2b）进行治疗，初始剂量为皮下注射500万单位，每周3次，但在某些情况下减至250万单位或增至1000万单位。治疗持续时间为15 - 36个月。7例患者通过流式细胞术显示循环B1阳性淋巴细胞明显减少。4例患者实现了持久的部分缓解（持续时间为106 - 134周），另有4例病情保持稳定。最初淋巴细胞计数最高（52,000/微升）的患者在28周后复发，仅在化疗64周后才实现病情控制。副作用为流感样症状和（2例）抑郁。3例患者血清免疫球蛋白浓度明显升高，这是IFNα-2b诱导免疫反应增强的迹象，而4例患者单核细胞上的HLA - DR表达增加了一倍。结论是，用IFNα-2b早期治疗CLL可能会延迟必要化疗的开始，可能改善任何抗体缺乏情况，并最终可能延长生存时间。
